256 related articles for article (PubMed ID: 25763933)
1. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
[TBL] [Abstract][Full Text] [Related]
2. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
Wang X; Xu L; Lao Y; Zhang H; Xu H
Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
[TBL] [Abstract][Full Text] [Related]
3. Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy.
Cheng W; Zhou J; Tian X; Zhang X
Curr Med Chem; 2016; 23(29):3343-3359. PubMed ID: 27160532
[TBL] [Abstract][Full Text] [Related]
4. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Han X; Hu L; Li Z; Geng Z; Wang Z; Zeng C; Xiao X
Anticancer Agents Med Chem; 2015; 15(2):267-73. PubMed ID: 25175686
[TBL] [Abstract][Full Text] [Related]
6. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
[TBL] [Abstract][Full Text] [Related]
7. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
[TBL] [Abstract][Full Text] [Related]
8. Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErbB Receptors.
Olivero-Acosta M; Maldonado-Rojas W; Olivero-Verbel J
Molecules; 2017 Feb; 22(2):. PubMed ID: 28218686
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
[TBL] [Abstract][Full Text] [Related]
10. Protein kinases as targets for developing anticancer agents from marine organisms.
Qiao G; Bi K; Liu J; Cao S; Liu M; Pešić M; Lin X
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129759. PubMed ID: 33038451
[TBL] [Abstract][Full Text] [Related]
11. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
Sabbah DA; Hajjo R; Sweidan K
Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
[TBL] [Abstract][Full Text] [Related]
12. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
Yassen AS; Elshihawy HE; Said MM; Abouzid KA
Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
[TBL] [Abstract][Full Text] [Related]
13. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
[TBL] [Abstract][Full Text] [Related]
14. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
17. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
18. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
Liang Y; Zhang T; Zhang J
Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
[TBL] [Abstract][Full Text] [Related]
19. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.
Mukherji D; Spicer J
Expert Opin Investig Drugs; 2009 Mar; 18(3):293-301. PubMed ID: 19243280
[TBL] [Abstract][Full Text] [Related]
20. Discovery of an EGFR tyrosine kinase inhibitor from Ilex latifolia in breast cancer therapy.
Wang C; Wang R; Chen Y; Wang L; Zhou S; Wang H
Bioorg Med Chem Lett; 2019 Jun; 29(11):1282-1290. PubMed ID: 30962086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]